Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of subcutaneous triptorelin pamoate 3‑month formulation in advanced prostate cancer
2012-001279-35Phase 3Completed
- Sponsor
- Ipsen
- Start
- Sep 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triptorelin pamoate in prostate cancer (PCa), sponsored by Ipsen. Primary endpoint: Proportion of patients castrated at primary time point. Started Sep 2012; status: completed.
02
Drugs
triptorelin pamoate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-001279-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001279-35.